Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

447.78 +10.56 (+2.42%)

Streaming Delayed Price Updated: 2:55 PM EDT, May 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗

Today 4:40 EDT

Via Chartmill

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

Which S&P500 stocks are moving on Tuesday? ↗

May 12, 2026

Via Chartmill

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗

May 11, 2026

The biotech's innovative platform could pay off.

Via The Motley Fool

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗

May 05, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗

May 04, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup ↗

April 29, 2026

Via Chartmill

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

May 11, 2026

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi...

Via StockStory

Topics Earnings

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 06, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗

May 06, 2026

The market wasn't impressed by its latest quarterly update.

Via The Motley Fool

Topics Initial Public Offering

Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗

May 04, 2026

Vertex (VRTX) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals Reports Mixed Q1 Results ↗

May 04, 2026

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday.

Via Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

May 04, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ...

Via StockStory

Vertex Reports First Quarter 2026 Financial Results

May 04, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗

May 04, 2026

Vertex (VRTX) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

May 02, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace...

Via StockStory

Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗

May 02, 2026

These longtime market beaters may not have peaked yet.

Via The Motley Fool

Topics World Trade

Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗

May 01, 2026

They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge.

Via The Motley Fool

Topics Credit Cards Economy

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗

April 30, 2026

These companies are leaders in their fields.

Via The Motley Fool

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗

April 30, 2026

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Via The Motley Fool

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗

April 30, 2026

This particular player has seen its yield rise in recent years.

Via The Motley Fool

3 Growth Stocks That Could Generate 10X Returns ↗

April 29, 2026

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Via The Motley Fool

Topics Cannabis Law Enforcement

3 of Wall Street’s Favorite Stocks Worth Your Attention

April 29, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

3 Market-Beating Stocks to Consider Right Now

April 28, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

Topics Energy

3 Healthcare Stocks With the Most Durable Competitive Moats ↗

April 23, 2026

These companies offer a clear path to sustained earnings growth.

Via The Motley Fool

Topics Intellectual Property

CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗

April 21, 2026

We'll know more about the company's medium-term prospects by the end of the year.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗

April 19, 2026

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Via The Motley Fool

Is Vertex Pharmaceuticals' Empire in Trouble? ↗

April 16, 2026

It might not be too late to invest in this company.

Via The Motley Fool

1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges

April 16, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.